<DOC>
	<DOCNO>NCT01456325</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled study evaluate efficacy safety onartuzumab ( MetMAb ) combination Tarceva ( erlotinib ) participant incurable non-small cell lung cancer identify Met diagnostic-positive . Participants randomize receive either onartuzumab ( MetMAb ) placebo combination erlotinib . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Onartuzumab ( MetMAb ) Combination With Tarceva ( Erlotinib ) Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced Metastatic Disease ( MetLung )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult participant , great equal ( &gt; /= ) 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Histologically cytologically confirm incurable Stage IIIb/IV NSCLC tumor Met diagnosticpositive status test immunohistochemistry ( IHC ) Results endothelial growth factor receptor ( EGFR ) activate mutation test Radiographic evidence disease Prior treatment least one platinumbased line treatment ( stage IIIb/IV ) one additional line chemotherapy treatment ; last dose chemotherapy must administer &gt; /= 21 day prior Day 1 availability tissue sample diagnostic testing require More 30 day exposure investigational market agent act EGFR inhibition , know EGFRrelated toxicity result dose modification ( EGFR inhibitor include limited gefitinib , erlotinib cetuximab ) Brain metastases spinal cord compression definitively treat surgery and/or radiation , previously treat central nervous system ( CNS ) metastases spinal cord compression without evidence stable disease &gt; /= 14 day History another malignancy previous 3 year , unless cure surgery alone continuously disease free least 3 year ; participant prior history noninvasive cancer eligible Inadequate hematological , biochemical organ function Significant history cardiac disease Serious active infection time randomization serious underlie medical condition would impair ability participant receive protocol treatment Any inflammatory change surface eye Clinically significant gastrointestinal disease , include uncontrolled inflammatory gastrointestinal disease Pregnant lactate woman Positive human immunodefinciency ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>